



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:) Examiner: Kemmerer, Elizabeth
Audrey Goddard, et al.)
Application Serial No. 09/902,713) Art Unit: 1646
Filed: July 10, 2001) Attorney's Docket No. 39780-1618 P2C34
For: **ANTIBODIES TO PRO269**)
POLYPEPETIDES)
Customer No. 35489)

EXPRESS MAIL LABEL NO. EL 976 543 854 US

Date Mailed: November 3, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Supplemental Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.


Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form Supplemental PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

- (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
 - (2) It is being filed within 3 months of entry of a national stage
-- OR --
 - (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
 - (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- a certification as specified in §1.97(e) is provided below; **or**
 - a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
 - B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
 - C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Attorney's Docket No. 39780-1618P2C34).

Respectfully submitted,

By: 
Leslie A. Mooi (Reg. No. 37,047)

Dated: November 3, 2004

HELLER EHRLMAN WHITE & McAULIFFE LLP
275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7000
Customer No. 35489

SUPPLEMENTAL FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT <i>(use several sheets if necessary)</i>				Attorney's Docket No. 39780-1618 P2C34	Application Serial No. 09/902,713		
				Applicant(s)	Audrey Goddard et al.		
				Filing Date: July 10, 2001	Group Art Unit: 1646		
U.S. PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
1.							
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation
2.							YES NO
OTHER DOCUMENTS <i>(including author, title, date, pertinent pages, etc.)</i>							
Examiner Initials	Ref. No.	Title					
	3.	Hyman, Elizabeth et al., "Impact of DNA Amplification on Gene Expression Patterns in Breast Cancer," <i>Cancer Research</i> , 62: 6240-6245, (2002).					
	4.	Ørntoftt§, Torben F. et al., "Genome-Wide Study of Gene Copy Numbers, Transcripts, and Protein Levels in Pairs of Non-Invasive and Invasive Human Transitional Cell Carcinomas," <i>Molecular & Cellular Proteomics</i> 1.1, 37-45 (2001).					
	5.	Pollack, Jonathan et al., "Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Alteration in the Transcriptional Program of Human Breast Tumors," <i>PNAS</i> , 99:(20) 12963-12968 (2002).					
	6.						
	7.						
	8.						
	9.						
	10.						
	11.						
	12.						
	13.						
	14.						
	15.						
	16.						
	17.						
	18.						
	19.						
	20.						
	21.						
	22.						
	23.						

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	
SV 2076790 v1	